Non-Invasive Liquid Biopsy Market - Global Forecast 2026-2032

The non-invasive liquid biopsy market is steadily gaining traction as healthcare stakeholders worldwide adopt advanced analytical platforms and diverse biomarkers to help reshape diagnostic strategies.

Market Snapshot: Non-Invasive Liquid Biopsy Market

The global non-invasive liquid biopsy market grew from USD 5.28 billion in 2025 to USD 5.77 billion in 2026. With a projected compound annual growth rate (CAGR) of 9.29%, expansion is anticipated through 2032, with the market forecast to reach USD 9.84 billion. This notable growth mirrors rising clinical adoption across disciplines, technological advancements, and growing confidence in non-invasive diagnostics as a viable alternative for cancer, infectious disease, and prenatal applications. Senior decision-makers are leveraging the evolving landscape to fortify diagnostics strategies, diversify portfolios, and capitalize on emerging healthcare needs.

Scope & Segmentation

Technology Modalities: Includes next generation sequencing (targeted, exome, and genome-level), digital PCR systems such as droplet-based and BEAMing formats, as well as quantitative PCR platforms. These diverse modalities enable stakeholders to address a variety of sample types and throughput needs, supporting both high-sensitivity detection and routine clinical workflows.
Clinical Applications: Spanning early cancer screening, longitudinal disease monitoring, infectious disease diagnostics, and prenatal testing. Specific use cases include assessing minimal residual disease and identifying chromosomal or genetic disorders, empowering risk stratification and early interventions.
Biomarker Classes: Includes cell free DNA (cfDNA), circulating tumor DNA (ctDNA), and exosomes. Each biomarker class offers differentiated analytical and clinical insights, helping refine diagnosis, monitor therapy response, and support precision medicine approaches.
End-User Segments: Encompasses commercial diagnostic laboratories prioritizing scale and standardization, hospital laboratories needing rapid integration with care delivery, and research institutes driving continuous innovation. Understanding user priorities enables tailored platform development and optimized workflow deployment.
Regional Coverage: Markets include the Americas—characterized by established regulatory pathways and integrated healthcare systems; Europe/Middle East & Africa—with varied healthcare environments and evolving standards; and Asia-Pacific—marked by domestic innovation and the expansion of laboratory capacities. Regional insight facilitates effective strategy localization and strengthens competitive positioning.

This multi-faceted segmentation allows executive teams to align technology investments, biomarker development, and geographic focus with evolving clinical and operational requirements in the non-invasive liquid biopsy market.

Key Takeaways: Strategic Trends in Non-Invasive Liquid Biopsy

Non-invasive liquid biopsy is transforming diagnostics by enabling longitudinal monitoring and disease detection with reduced patient risk and faster result turnaround, fostering patient-centric care delivery.
With mounting clinical evidence, liquid biopsy workflows are being actively integrated into routine care, supporting multi-analyte analysis to enhance contextual diagnostic insights and enable precision medicine initiatives.
Collaborative technology partnerships drive workflow automation, increasing adoption and providing scalability across both hospital laboratories and large reference diagnostic networks.
Regional differences in healthcare infrastructure, regulation, and readiness dictate the necessity for tailored market entry, validation, and partnership approaches, ensuring adaptability amid local market dynamics.
Segmented strategies inform product development and go-to-market planning by mapping platform capabilities directly to end-user priorities and specific market needs, driving alignment between innovation and commercial outcomes.

Tariff Impact: Navigating Supply Chain and Procurement Challenges

Recent United States tariffs imposed in 2025 drove diagnostic providers to reassess procurement strategies. The resulting rise in component costs and supply uncertainty led many laboratories and vendors to expand supplier diversification, explore nearshoring, and invest in predictive procurement models. Vertical integration gained prominence as a means to mitigate disruptions and strengthen supply chain stability. These tariff-related shifts have prompted broader industry emphasis on streamlined inventory management, increased workflow efficiency, and proactive cost containment. Sector-wide discussions now focus on building more resilient supply chains and evaluating the benefits of local manufacturing for long-term operational assurance.

Methodology & Data Sources

Research insights are informed by primary interviews with laboratory directors, suppliers, and researchers, supplemented by expert validation and analysis of publicly available literature and regulatory guidance. The methodology incorporates scenario analysis and cross-validation of sensitivity, specificity, and workflow metrics to support robust, relevant, and actionable recommendations for executive planning.

Why This Report Matters

Enables precise technology selection and market entry strategies by mapping platform strengths to targeted clinical use cases and regional growth opportunities within the non-invasive liquid biopsy market.
Supports operational planning by dissecting the impact of tariffs, advancing supply chain adaptation, and leveraging clinical utility data to guide decision-making and ensure resilience.
Provides clarity for business development, partnership formation, and regulatory navigation, helping align innovation with evolving market demands and drive sustainable value creation.

Conclusion

Advancements in liquid biopsy detection, clinical validation, and operational workflows are fueling broader adoption. Senior decision-makers equipped with actionable insights from this report can confidently navigate changing dynamics, sustain growth, and deliver greater impact in the non-invasive diagnostics market.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Invasive Liquid Biopsy Market, by Technology

8.1. Digital PCR
8.1.1. BEAMing
8.1.2. Droplet Digital PCR
8.2. Next Generation Sequencing
8.2.1. Targeted Sequencing
8.2.2. Whole Exome Sequencing
8.2.3. Whole Genome Sequencing
8.3. Quantitative PCR

9. Non-Invasive Liquid Biopsy Market, by Biomarker

9.1. Cell Free DNA
9.2. Circulating Tumor DNA
9.3. Exosomes

10. Non-Invasive Liquid Biopsy Market, by Sample Type

10.1. Stool
10.2. Urine
10.3. Saliva

11. Non-Invasive Liquid Biopsy Market, by Application

11.1. Cancer Screening
11.1.1. Early Detection
11.1.2. Minimal Residual Disease Monitoring
11.2. Infectious Disease Diagnostics
11.3. Prenatal Testing
11.3.1. Chromosomal Abnormality Screening
11.3.2. Single Gene Disorder Screening

12. Non-Invasive Liquid Biopsy Market, by End User

12.1. Commercial Laboratories
12.2. Hospital Laboratories
12.3. Research Institutes

13. Non-Invasive Liquid Biopsy Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Non-Invasive Liquid Biopsy Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Non-Invasive Liquid Biopsy Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Non-Invasive Liquid Biopsy Market
17. China Non-Invasive Liquid Biopsy Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Angle PLC
18.6. Bio-Rad Laboratories, Inc.
18.7. Bio-Techne Corporation
18.8. Biocept, Inc.
18.9. DiaCarta, Inc.
18.10. Epic Sciences Inc.
18.11. F. Hoffmann-La Roche Ltd.
18.12. Grail, Inc.
18.13. Guardant Health, Inc.
18.14. Illumina, Inc.
18.15. Integrated DNA Technologies, Inc.
18.16. Laboratory Corporation of America Holdings
18.17. Lonza Group Ltd.
18.18. Lucence Diagnostics Pte. Ltd.
18.19. LungLife AI, Inc.
18.20. Mdxhealth BV
18.21. MedGenome Labs Ltd.
18.22. Menarini Silicon Biosystems SpA
18.23. Merck KGaA
18.24. Natera, Inc.
18.25. Nonacus Limited
18.26. Norgen Biotek Corporation
18.27. Oasis Diagnostics Corporation
18.28. OraSure Technologies, Inc
18.29. QIAGEN GmbH
18.30. Thermo Fisher Scientific Inc.
18.31. Zymo Research Corp.

List of Figures

FIGURE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 127. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 128. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 129. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 132. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 133. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 146. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 147. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 148. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 149. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 150. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 152. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 153. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 167. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 168. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 169. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 170. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 171. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 172. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 173. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 174. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 177. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 178. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 179. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 180. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 181. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 183. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 184. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 197. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 198. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 199. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 200. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 201. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 202. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 203. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 204. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 207. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 208. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 209. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 210. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 211. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 212. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 213. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 214. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 218. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 219. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 220. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 221. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 223. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 224. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 238. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 239. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 240. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
TABLE 241. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 242. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 243. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
TABLE 244. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
TABLE 245. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Non-Invasive Liquid Biopsy market report include:

Angle PLC
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
Biocept, Inc.
DiaCarta, Inc.
Epic Sciences Inc.
F. Hoffmann-La Roche Ltd.
Grail, Inc.
Guardant Health, Inc.
Illumina, Inc.
Integrated DNA Technologies, Inc.
Laboratory Corporation of America Holdings
Lonza Group Ltd.
Lucence Diagnostics Pte. Ltd.
LungLife AI, Inc.
Mdxhealth BV
MedGenome Labs Ltd.
Menarini Silicon Biosystems SpA
Merck KGaA
Natera, Inc.
Nonacus Limited
Norgen Biotek Corporation
Oasis Diagnostics Corporation
OraSure Technologies, Inc
QIAGEN GmbH
Thermo Fisher Scientific Inc.
Zymo Research Corp.

Table Information

Report Attribute	Details
No. of Pages	198
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 5.77 Billion
Forecasted Market Value ( USD ) by 2032	$ 9.84 Billion
Compound Annual Growth Rate	9.2%
Regions Covered	Global
No. of Companies Mentioned	28

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3471EUR$3,939USD£3,022GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3745EUR$4,249USD£3,259GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5075EUR$5,759USD£4,418GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6142EUR$6,969USD£5,346GBP

Market Snapshot: Non-Invasive Liquid Biopsy Market

Scope & Segmentation

Key Takeaways: Strategic Trends in Non-Invasive Liquid Biopsy

Tariff Impact: Navigating Supply Chain and Procurement Challenges

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

Liquid Biopsy Market - Global Forecast 2026-2032

Competitive Landscape of Liquid Biopsy Market, Forecast by Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue

Lung Cancer Liquid Biopsy Global Market Report 2025

Liquid Biopsy Market Report 2025